Stroke prevention in patients with atrial fibrillation in France: Comparative cost-effectiveness of new oral anticoagulants (apixaban, dabigatran, and rivaroxaban), warfarin, and aspirin

Journal of Medical Economics

Volumn 17, Issue 8, 2014, Pages 587-598

  Lanitis, T ^a   Cotte F E ^b   Gaudin, A F ^b   Kachaner, I ^c   Kongnakorn, T ^a   Durand Zaleski, I ^d  

^a EVIDERA   (United Kingdom)

^b BRISTOL MYERS SQUIBB   (United States)

^c PFIZER INC   (United States)

^d Paris Health Economics and Health Services Research Unit (URC Eco)   (France)

Author keywords

Anticoagulation; Apixaban; Atrial fibrillation; Cost effectiveness; Efficiency frontier; Warfarin

Indexed keywords

ACETYLSALICYLIC ACID; APIXABAN; DABIGATRAN; RIVAROXABAN; WARFARIN; ANTICOAGULANT AGENT; ANTITHROMBIN; BENZIMIDAZOLE DERIVATIVE; BETA ALANINE; BLOOD CLOTTING FACTOR 10A INHIBITOR; MORPHOLINE DERIVATIVE; PYRAZOLE DERIVATIVE; PYRIDONE DERIVATIVE; THIOPHENE DERIVATIVE;

AGED; ARTICLE; BRAIN EMBOLISM; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; FRANCE; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HOSPITALIZATION; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; NEUROPROTECTION; QUALITY ADJUSTED LIFE YEAR; TREATMENT OUTCOME; ANALOGS AND DERIVATIVES; ATRIAL FIBRILLATION; COMPLICATION; COST BENEFIT ANALYSIS; ECONOMICS; STROKE;

ANTICOAGULANTS; ANTITHROMBINS; ASPIRIN; ATRIAL FIBRILLATION; BENZIMIDAZOLES; BETA-ALANINE; COMPARATIVE EFFECTIVENESS RESEARCH; COST-BENEFIT ANALYSIS; FACTOR XA INHIBITORS; FEMALE; FRANCE; HUMANS; MALE; MORPHOLINES; PYRAZOLES; PYRIDONES; QUALITY-ADJUSTED LIFE YEARS; STROKE; THIOPHENES; WARFARIN;

EID: 84904598938     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2014.923891     Document Type: Article

References (44)

1. Hanon OAP, Belmin J, Collet JP, et al. Expert consensus of the French Society of Geriatrics and Gerontology and the French Society of Cardiology on the management of atrial fibrillation in elderly people. Arch Cardiovasc Dis 2013;106:302-23
2. Fery-Lemonnier E. La prévention et la prise en charge des accidents vasculaires cé ré braux en France: Synthèse du rapport à Madame la ministre de la santé et des sports. Ministere De La Sante Et Des Sports, 2009. Available at: http://www.sante.gouv.fr/IMG/pdf/ AVC-synthese-seule- rapport-final-vf.pdf
3. Chevreul K, Durand-Zaleski I, Gouepo A, et al. Cost of stroke in France. Eur J Neurol 2013;20:1094-100
4. ISMAAP. International Self Monitoring Association of oral Anticoagulated patients. Available at: http://www.ismaap.org
5. Bassand JP. Review of atrial fibrillation outcome trials of oral anticoagulant and antiplatelet agents. Europace 2012;14:312-24
6. Fauchier L, Taillandier S, Clementy N. [Antithrombotic management in atrial fibrillation]. Rev Prat 2013;63:199, 201-6
7. Le Reste JY CB, Le Floch B, Nabbe P, et al. There are considerable drawbacks to oral anticoagulant for monitoring patients at home which should lead family physicians to discuss alternative or enhanced solutions: a cross-sectional study. BMC Cardiovasc Disord 2013;13:71
8. Liard F, Le Heuzey JY, Aliot E, et al. [Atrial fibrillation and anticoagulation: general practitioner, cardiologist and patient's points of view]. Presse Med 2013;42:e259-70
9. Mabo P, Leenhardt A, Jaillon P, et al. [Management of atrial fibrillation in France: the observational FACTUEL study]. Ann Cardiol Angeiol (Paris) 2009;58:151-8
10. Camm AJ, Lip GY, De Caterina R, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012;33:2719-47
11. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-51
12. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in non-valvular atrial fibrillation. N Engl J Med 2011;365:883-91
13. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365:981-92
14. Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation. N Engl J Med 2011;364:806-17
15. Heidbuchel HPV, Alings M, Antz M, et al. EHRA Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary. Eur Heart J. 2013;34:2094-106
16. Elewa HF, Deremer CE, Keller K, et al. Patients satisfaction with warfarin and willingness to switch to dabigatran: a patient survey. J Thromb Thrombolysis 2013 (epub ahead of print)
17. Choi JC, Dibonaventura MD, Kopenhafer L, et al. Survey of the use of warfarin and the newer anticoagulant dabigatran in patients with atrial fibrillation. Patient Prefer Adherence 2014;8:167-77
18. Attaya S, Bornstein T, Ronquillo N, et al. Study of warfarin patients investigating attitudes toward therapy change (SWITCH Survey). Am J Ther 2012;19:432-5
19. Dervaux B, Baseilhac E, Fagon JY, et al. Medico-economic evaluation of health products in the context of the Social Security Financing Act for 2012. Therapie 2013;68:253-63
20. Dorian P, Kongnakorn T, Phatak H, et al. Cost-effectiveness of apixaban vs. current standard of care for stroke prevention in patients with atrial fibrillation. Eur Heart J 2014 (epub ahead of print)
21. Lip GY, Kongnakorn T, Phatak H, et al. Cost-effectiveness of apixaban versus other new oral anticoagulants for stroke prevention in atrial fibrillation. Clin Ther 2014;36:192-210
22. Bucher HC, Guyatt GH, Griffith LE, et al. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 1997;50:683-91
23. Haute autorité de santé (HAS). A methodological guide. Choices in methods for economic evaluation. Department of Economics and Public Health Assessment, 2012. Available at: http://www.has-sante.fr
24. Cotte FE, Chaize G, Kachaner I, et al. Incidence and cost of stroke and hemorrhage in patients diagnosed with atrial fibrillation in France. J Stroke Cerebrovasc Dis 2014;23:e73-83
25. Ministry of Health. National Hospital Tariff. Official Journal of the French Republic. 2011. Available at: http://www.journal-officiel.gouv.fr.
26. Cohen A, Dallongeville J, Durand-Zaleski I, et al. Characteristics and management of outpatients with history of or current atrial fibrillation: the observational French EPHA study. Arch Cardiovasc Dis 2010;103:376-87
27. Pricing Comittee (CEPS). Drug price database for France. Available at: http://www.medicprix.sante.gouv.fr. Last accessed 31st December 2013
28. National Health Insurance Fund for Salaried Worker (CNAMTS). National tariffs for biological and nursing acts. 2011. Available at: http://www.ameli.fr
29. Haute autorité de santé (HAS). Fibrillation auriculaire. Available at: www.has-sante.fr Accessed Juillet 200.
30. Ministry of Health. Prevention and management of stroke in France. 2009. Available at: http://www.sante.gouv.fr/IMG/pdf/AVC-rapport- final-vf.pdf
31. Sullivan P, Slejko J, Sculpher M, et al. Catalogue of EQ-5D scores for the United Kingdom. Med Decis Making 2011;31:800-4
32. Gage BF CA, Owens DK. The effect of stroke and stroke prophylaxis with aspirin or warfarin on quality of life. JAMA Intern Med 1996;156: 1829-36
33. Caro JJ, Nord E, Siebert U, et al. The efficiency frontier approach to economic evaluation of health-care interventions. Health Econ 2010;19:1117-27
34. Wallentin L, Lopes RD, Hanna M, et al. Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation. Circulation 2013;127:2166-76
35. Baker WL, Phung OJ. Systematic review and adjusted indirect comparison meta-analysis of oral anticoagulants in atrial fibrillation. Circ Cardiovasc Qual Outcomes 2012; 5: 7119
36. Coyle D, Coyle K, Cameron C, et al. Cost-effectiveness of new oral anticoagulants compared with warfarin in preventing stroke and other cardiovascular events in patients with atrial fibrillation. Value Health 2013;16: 498-506
37. Harrington AR, Armstrong EP, Nolan Jr. PE, et al. Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation. Stroke 2013;44:1676-81
38. Pink J, Pirmohamed M, Hughes DA. Comparative effectiveness of dabigatran, rivaroxaban, apixaban, and warfarin in the management of patients with nonvalvular atrial fibrillation. Clin Pharmacol Ther 2013;94:269-76
39. Psaty BM, Prentice RL. Minimizing bias in randomized trials: the importance of blinding. JAMA 2010;304:793-4
40. Carrasco J, Cotté FE, Duprat Lomon I, et al. Anticoagulation treatment with VKA in France, Italy, Germany, Spain and United Kingdom. Results from the React AF study. Value in Health 2013;16:A516
41. Lip GY, Larsen TB, Skjoth F, et al. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation. J Am Coll Cardiol 2012;60:738-46
42. Schneeweiss S, Gagne JJ, Patrick AR, et al. Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation. Circ Cardiovasc Qual Outcomes 2012;5:480-6
43. Davis NJ, Billett HH, Cohen HW, et al. Impact of adherence, knowledge, and quality of life on anticoagulation control. Ann Pharmacother 2005;39: 632-6
44. Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013;369:2093-104